Elisa Yaniz‐Galende

Inserm — France

Medicine · Health Sciences

10h-index431citations61works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiomics and Machine Learning in Medical Imaging(25), Cardiac Fibrosis and Remodeling(13), Cancer Research and Treatments(12), Ovarian cancer diagnosis and treatment(11), Congenital heart defects research(10)

Publications61 total

Abstract A011: Rationale for the use of Azenosertib in Early Line Treatment of Cyclin E1-Positive High-Grade Serous Ovarian Cancer
Molecular Cancer Therapeutics·2025
Assessing the Status of Cyclin E1 (CCNE1) From Gene to Protein Level in Ovarian and Endometrial Carcinomas: A Systematic Review
Laboratory Investigation·2025· 1 cited
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Molecular Cancer·2024· 10 citedOpen Access
Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S7 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S7 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Alexandra Léary(27), Catherine Genestie(24), Félix Blanc‐Durand(21), Alain Lortholary(21), Éric Pujade-Lauraine(21), Laure Chardin(21), Nadine Dohollou(20), Christophe Desauw(20), Michel Fabbro(20), Emmanuelle Malaurie(20), Gwénaël Ferron(20), Audrey Le Formal(20), Isabelle Ray‐Coquard(19), Dominique Berton-Rigaud(19), Christophe Klein(18), Étienne Rouleau(18), Elodie Edmond(18), Patricia Pautier(18), Qinghe Zeng(17), Virginie Marty(17)